Emerging technologies for point-of-care management of HIV infection

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 387-405

  Shafiee, Hadi ^a   Wang, Shu Qi ^b   Inci, Fatih ^b   Toy, Mehlika ^c   Henrich, Timothy J ^a   Kuritzkes, Daniel R ^a   Demirci, Utkan ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

AIDS; CD4 cell count; diagnostics; micro and nanotechnology; viral load

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAG PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYZER; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BIOSENSOR; CD4 LYMPHOCYTE COUNT; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG MONITORING; DRUG RESISTANCE TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETER; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMAGE PROCESSING; NUCLEIC ACID ANALYSIS; PANDEMIC; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCREENING; TECHNOLOGY; TREATMENT OUTCOME; VIRUS LOAD; WESTERN BLOTTING; ANTIVIRAL RESISTANCE; DISEASE MANAGEMENT; FLOW CYTOMETRY; HIV INFECTIONS; HOSPITAL INFORMATION SYSTEM; IMMUNOLOGY; MICROFLUIDIC ANALYSIS;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE MANAGEMENT; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; MICROFLUIDIC ANALYTICAL TECHNIQUES; POINT-OF-CARE SYSTEMS; POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 84921417617     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-092112-143017     Document Type: Article

References (100)

1. Bor J, Herbst AJ, Newell ML, Barnighausen T. 2013. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339:961-65
2. CohenMS, Chen YQ, McCauleyM, et al. 2011. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365:493-505
3. World Health Organization 2013. Global update on HIV treatment 2013: results, impact and opportunities. http://www.who.int/hiv/pub/progressreports/update2013/en/
4. WorldHealthOrganization 2014. WorldHealth Statistics. http://apps.who.int/iris/bitstream/10665/112738/1/9789240692671-eng.pdf?ua=1
5. WorldHealthOrganization 2014. Global updtate on the health sector response toHIV. http://www.who.int/hiv/pub/progressreports/update2014/en/
6. UNAIDS 2011. Global HIV/AIDS response: epidemic update and health sector progress towards Universal Access. http://www.unaids.org/sites/default/files/media-Asset/20111130-UA-Report-en-1.pdf
7. Creek TL, Sherman GG, Nkengasong J, et al. 2007. Infant human immunodeficiency virus diagnosis in resource-limited settings: issues, technologies, and country experiences. Am. J. Obstet. Gynecol. 197:S64-71
8. Persaud D, Gay H, Ziemniak C, et al. 2013. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369:1828-35
9. UNITAID 2014. HIV/AIDS Diagnostic Technology Landscape: 4th Edition. http://www.unitaid.eu/images/marketdynamics/publications/UNITAID-HIV-Diagnostic-Landscape-4th-edition.pdf
10. Wang S, Xu F, Demirci U. 2010. Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol. Adv. 28:770-81
11. Rosenberg NE, Kamanga G, Phiri S, et al. 2012. Detection of acute HIV infection: a field evaluation of the Determine R-HIV-1/2 Ag/Ab Combo test. J. Infect. Dis. 205:528-34
12. Gray RH, Makumbi F, Serwadda D, et al. 2007. Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ 335:188-91
13. Powers KA, Ghani AC, MillerWC, et al. 2011. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 378:256-68
14. Mellors JW, Munoz A, Giorgi JV, et al. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126:946-54
15. Braitstein P, BrinkhofMW, Dabis F, et al. 2006. Mortality ofHIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367:817-24
16. Vitoria M, Vella S, Ford N. 2013. Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. Curr. Opin. HIV AIDS 8:12-18
17. Hoare A, Kerr SJ, Ruxrungtham K, et al. 2010. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLOS ONE 5:e10981
18. vanOosterhout JJ, Brown L, Weigel R, et al. 2009. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop. Med. Int. Health 14:856-61
19. Medecins Sans Frontieres Access Campaign 2013. Putting HIV treatment to the test: a product guide for viral load and point-of-care CD4 diagnostic tools. http://www.msfaccess.org/sites/default/files/HIV-Report-VL-ENG-2013-0.pdf
20. Yager P, Domingo GJ, Gerdes J. 2008. Point-of-care diagnostics for global health. Annu. Rev. Biomed. Eng. 10:107-44
21. Wang S, Inci F, De Libero G, et al. 2013. Point-of-care assays for tuberculosis: role of nanotechnology/microfluidics. Biotechnol. Adv. 31:438-49
22. Louie RF, Ferguson WJ, Curtis CM, et al. 2014. Vulnerability of point-of-care test reagents and instruments to environmental stresses: implications for health professionals and developers. Clin. Chem. Lab. Med. 52:325-35
23. Wang S, Inci F, Chaunzwa TL, et al. 2012. Portable microfluidic chip for detection of Escherichia coli in produce and blood. Int. J. Nanomed. 7:2591-2600
24. Boyle DS, Hawkins KR, Steele MS, et al. 2012. Emerging technologies for point-of-care CD4 T-lymphocyte counting. Trends Biotechnol. 30:45-54
25. Cheng X, Liu YS, Irimia D, et al. 2007. Cell detection and counting through cell lysate impedance spectroscopy in microfluidic devices. Lab. Chip 7:746-55
26. Holmes D, Morgan H. 2010. Single cell impedance cytometry for identification and counting of CD4 T-cells in human blood using impedance labels. Anal. Chem. 82:1455-61
27. Watkins NN, Sridhar S, Cheng X, et al. 2011. A microfabricated electrical differential counter for the selective enumeration of CD4+ T lymphocytes. Lab. Chip 11:1437-47
28. Alyassin MA, Moon S, Keles HO, et al. 2009. Rapid automated cell quantification on HIV microfluidic devices. Lab. Chip 9:3364-69
29. Moon S, Gurkan UA, Blander J, et al. 2011. Enumeration of CD4+ T-cells using a portable microchip count platform in Tanzanian HIV-infected patients. PLOS ONE 6:e21409
30. Moon S, KelesHO, Ozcan A, et al. 2009. Integratingmicrofluidics and lensless imaging for point-of-care testing. Biosens. Bioelectron. 24:3208-14
31. Gurkan UA, Moon S, Geckil H, et al. 2011. Miniaturized lensless imaging systems for cell and microorganism visualization in point-of-care testing. Biotechnol. J. 6:138-49
32. Jokerst JV, Floriano PN, Christodoulides N, et al. 2008. Integration of semiconductor quantum dots into nano-bio-chip systems for enumeration of CD4+ T cell counts at the point-of-need. Lab. Chip 8:2079-90
33. Rodriguez WR, Christodoulides N, Floriano PN, et al. 2005. A microchip CD4 counting method for HIV monitoring in resource-poor settings. PLOS Med. 2:e182
34. Gallegos D, LongKD, Yu H, et al. 2013. Label-free biodetection using a smartphone. Lab. Chip 13:2124-32
35. Wang S, Zhao X, Khimji I, et al. 2011. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care. Lab. Chip 11:3411-18
36. Wang Z, Chin SY, Chin CD, et al. 2010. Microfluidic CD4+ T-cell counting device using chemiluminescence-based detection. Anal. Chem. 82:36-40
37. Wang S, Tasoglu S, Chen PZ, et al. 2014. Micro-A-fluidics ELISA for rapid CD4 cell count at the point-of-care. Sci. Rep. 4:3796
38. World Health Organization. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng. pdf?ua=1
39. Stevens WS, Scott LE, Crowe SM. 2010. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J. Infect. Dis. 201(Suppl. 1):S16-26
40. Tanriverdi S, Chen L, Chen S. 2010. A rapid and automated sample-To-result HIV load test for nearpatient application. J. Infect. Dis. 201(Suppl. 1):S52-58
41. Usdin M, Guillerm M, Calmy A. 2010. Patient needs and point-of-care requirements for HIV load testing in resource-limited settings. J. Infect. Dis. 201(Suppl. 1):S73-77
42. Labbett W, Garcia-Diaz A, Fox Z, et al. 2009. Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load. J. Clin. Microbiol. 47:3266-70
43. Mine M, Bedi K, Maruta T, et al. 2009. Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a decentralization pilot study. J. Virol. Methods 159:93-97
44. Drosten C, Panning M, Drexler JF, et al. 2006. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-Time reverse transcription-PCR assay with internal control for the 5-long terminal repeat domain. Clin. Chem. 52:1258-66
45. Rouet F, Ekouevi DK, Chaix ML, et al. 2005. Transfer and evaluation of an automated, low-cost realtime reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43:2709-17
46. Tang W, Chow WH, Li Y, et al. 2010. Nucleic acid assay system for tier II laboratories and moderately complex clinics to detect HIV in low-resource settings. J. Infect. Dis. 201(Suppl. 1):S46-51
47. Lee HH, Dineva MA, Chua YL, et al. 2010. Simple amplification-based assay: a nucleic acid-based point-of-care platform for HIV-1 testing. J. Infect. Dis. 201(Suppl. 1):S65-72
48. Jangam SR, Agarwal AK, Sur K, Kelso DM. 2013. A point-of-care PCR test for HIV-1 detection in resource-limited settings. Biosens. Bioelectron. 42:69-75
49. Zhang C, Xing D. 2007. Miniaturized PCR chips for nucleic acid amplification and analysis: latest advances and future trends. Nucleic Acids Res. 35:4223-37
50. Johnston MI, Fauci AS. 2008. An HIV vaccine-challenges and prospects. N. Engl. J. Med. 359:888-90
51. Burton DR, Desrosiers RC, Doms RW, et al. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-36
52. Wang S, Esfahani M, Gurkan UA, et al. 2012. Efficient on-chip isolation of HIV subtypes. Lab. Chip 12:1508-15
53. Kim YG, Moon S, Kuritzkes DR, Demirci U. 2009. Quantum dot-based HIV capture and imaging in a microfluidic channel. Biosens. Bioelectron. 25:253-58
54. Shafiee H, Jahangir M, Inci F, et al. 2013. Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. Small 9:2553-63
55. Larguinho M, Baptista PV. 2012. Gold and silver nanoparticles for clinical diagnostics-from genomics to proteomics. J. Proteomics 75:2811-23
56. Wang S, Sarenac D, Chen MH, et al. 2012. Simple filter microchip for rapid separation of plasma and viruses from whole blood. Int. J. Nanomed. 7:5019-28
57. Ozcan A, Demirci U. 2008. Ultra wide-field lens-free monitoring of cells on-chip. Lab. Chip 8:98-106
58. Inci F, Tokel O, Wang S, et al. 2013. Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. ACS Nano 7:4733-45
59. ShafieeH, Caldwell J, Davalos R. 2010. Amicrofluidic system for biological particle enrichment utilizing contactless dielectrophoresis. J. Assoc. Lab. Autom. 15:224-32
60. Shafiee H, Sano MB, Henslee EA, et al. 2010. Selective isolation of live/dead cells using contactless dielectrophoresis (cDEP). Lab. Chip 10:438-45
61. Salmanzadeh A, Romero L, Shafiee H, et al. 2012. Isolation of prostate tumor initiating cells (TICs) through their dielectrophoretic signature. Lab. Chip 12:182-89
62. Shafiee H, Jahangir M, Inci F, et al. 2012. Towards point-of-care HIV-1 detection through electrical sensingon-A-chip. Presented at Am. Inst. Chem. Eng. Annu. Meet., Pittsburgh, PA
63. Mok J, Mindrinos MN, Davis RW, Javanmard M. 2014. Digital microfluidic assay for protein detection. Proc. Natl. Acad. Sci. USA 111:2110-15
64. Tokel O, Inci F, Demirci U. 2014. Advances in plasmonic technologies for point of care applications. Chem. Rev. 114:5728-52
65. Shamah SM, Cunningham BT. 2011. Label-free cell-based assays using photonic crystal optical biosensors. Analyst 136:1090-102
66. Shafiee H, Lidstone EA, Jahangir M, et al. 2014. Nanostructured optical photonic crystal biosensor for HIV viral load measurement. Sci. Rep. 4:1-7. doi: 10.1038/srep04116
67. Tang S, Hewlett I. 2010. Nanoparticle-based immunoassays for sensitive and early detection of HIV-1 capsid (p24) antigen. J. Infect. Dis. 201(Suppl. 1):S59-64
68. de la Rica R, Stevens MM. 2012. Plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye. Nat. Nanotechnol. 7:821-24
69. Prado JG, Shintani A, Bofill M, et al. 2004. Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic HIV infection during structured treatment interruptions. J. Clin. Microbiol. 42:1620-25
70. Stevens G, Rekhviashvili N, Scott LE, et al. 2005. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J. Clin. Microbiol. 43:857-61
71. Branson BM, Handsfield HH, Lampe MA, et al. 2006. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm. Rep. 55:1-17
72. Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. 2004. Rapid HIV-1 testing during labor: a multicenter study. JAMA 292:219-23
73. Galiwango RM, Musoke R, Lubyayi L, et al. 2013. Evaluation of current rapid HIV test algorithms in Rakai, Uganda. J. Virol. Methods 192:25-27
74. Franco-Paredes C, Tellez I, del RioC. 2006. RapidHIV testing: a review of the literature and implications for the clinician. Curr. HIV/AIDS Rep. 3:169-75
75. Laperche S, Leballais L, Ly TD, Plantier JC. 2012. Failure in the detection of HIV p24 antigen with the Determine HIV-1/2 Ag/Ab Combo rapid test. J. Infect. Dis. 206:1946-47
76. Chin CD, LaksanasopinT, Cheung YK, et al. 2011. Microfluidics-based diagnostics of infectious diseases in the developing world. Nat. Med. 17:1015-19
77. Linder V, Sia SK, Whitesides GM. 2005. Reagent-loaded cartridges for valveless and automated fluid delivery in microfluidic devices. Anal. Chem. 77:64-71
78. Little SJ, Holte S, Routy JP, et al. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-94
79. Lazzarin A, Clotet B, CooperD, et al. 2003. Efficacy of enfuvirtide in patients infectedwith drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2186-95
80. Clavel F, Hance AJ. 2004. Medical progress: HIV drug resistance. N. Engl. J. Med. 350:1023-35
81. Petropoulos CJ, Parkin NT, Limoli KL, et al. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-28
82. KuritzkesDR, Grant RM, Feorino P, et al. 2003. Performance characteristics of the TRUGENE HIV-1 genotyping kit and the Opengene DNA sequencing system. J. Clin. Microbiol. 41:1594-99
83. Eshleman SH, Hackett J, Swanson P, et al. 2004. Performance of the Celera Diagnostics ViroSeq HIV-1 genotyping system for sequence-base analysis of diverse human immunodeficiency virus type 1 strains. J. Clin. Microbiol. 42:2711-17
84. Mayer KH. 2001. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin. Infect. Dis. 32:774-82
85. Xu F, Wu J, Wang S, et al. 2011. Microengineering methods for cell-based microarrays and highthroughput drug-screening applications. Biofabrication 3:1-13. doi: 10.1088/1758-5082/3/3/034101
86. Yetisen AK, AkramMS, LoweCR. 2013. Paper-based microfluidic point-of-care diagnostic devices. Lab. Chip 13:2210-51
87. Coskun AF, Wong J, Khodadadi D, et al. 2013. A personalized food allergen testing platform on a cellphone. Lab. Chip 13:636-40
88. Mudanyali O, Dimitrov S, Sikora U, et al. 2012. Integrated rapid-diagnostic-Test reader platform on a cellphone. Lab. Chip 12:2678-86
89. Breslauer DN, Maamari RN, Switz NA, et al. 2009. Mobile phone based clinical microscopy for global health applications. PLOS ONE 4:e6320
90. Smith ZJ, Chu K, Espenson AR, et al. 2011. Cell-phone-based platform for biomedical device development and education applications. PLOS ONE 6:e17150
91. Martinez AW, Phillips ST, Butte MJ, Whitesides GM. 2007. Patterned paper as a platform for inexpensive, low-volume, portable bioassays. Angew. Chem. Int. Ed. 46:1318-20
92. Martinez AW, Phillips ST, Whitesides GM, Carrilho E. 2010. Diagnostics for the developing world: microfluidic paper-based analytical devices. Anal. Chem. 82:3-10
93. Dungchai W, Chailapakul O, Henry CS. 2009. Electrochemical detection for paper-based microfluidics. Anal. Chem. 81:5821-26
94. Rohrman BA, Richards-Kortum RR. 2012. A paper and plastic device for performing recombinase polymerase amplification of HIV DNA. Lab. Chip 12:3082-88
95. Wang S, Ge L, Zhang Y, et al. 2012. Battery-Triggeredmicrofluidic paper-based multiplex electrochemiluminescence immunodevice based on potential-resolution strategy. Lab. Chip 12:4489-98
96. Ge L, Wang S, Song X, et al. 2012. 3D origami-based multifunction-integrated immunodevice: lowcost and multiplexed sandwich chemiluminescence immunoassay on microfluidic paper-based analytical device. Lab. Chip 12:3150-58
97. Carrilho E, Phillips ST, Vella SJ, et al. 2009. Paper microzone plates. Anal. Chem. 81:5990-98
98. Bergeron M, Daneau G, Ding T, et al. 2012. Performance of the PointCare NOW system for CD4 counting in HIV patients based on five independent evaluations. PLOS ONE 7:e41166
99. Glencross DK, Coetzee LM, Faal M, et al. 2012. Performance evaluation of the Pima point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa. J. Int. AIDS Soc. 15:1-13. doi: 10.1186/1758-2652-15-3
100. Watkins NN, Hassan U, Damhorst G, et al. 2013. Microfluidic CD4+ and CD8+ T lymphocyte counters for point-of-care HIV diagnostics using whole blood. Sci. Transl. Med. 5:1-11. doi: 10.1126/scitranslmed.3006870